This company seems to have been delisted
Reason: Acquired by AbbVie
Last recorded trade on: April 12, 2024
Source: https://news.abbvie.com/2024-02-12-AbbVie-Completes-Acquisition-of-ImmunoGen
Reason: Acquired by AbbVie
Last recorded trade on: April 12, 2024
Source: https://news.abbvie.com/2024-02-12-AbbVie-Completes-Acquisition-of-ImmunoGen
ImmunoGen
IMGN
NZ$51.49
Share price
0.00%
Change (1 day)
136.73%
Change (1 year)
Categories
ImmunoGen (IMGN) - Total assets
Total assets on the balance sheet as of September 2023 : NZ$1.35 Billion
According to ImmunoGen 's latest financial reports the company's total assets are NZ$1.35 Billion. A company’s total assets is the sum of all current and non-current assets, such as inventories, cash and cash equivalents, properties and equipment.
ImmunoGen - Total assets on balance sheet (from 2001 to 2023)
Total assets by year
| Year | Total assets | Change |
|---|---|---|
| 2022-12-31 | NZ$0.54 B | -28.6% |
| 2021-12-31 | NZ$0.76 B | 56.42% |
| 2020-12-31 | NZ$0.49 B | 40.87% |
| 2019-12-31 | NZ$0.34 B | -20.67% |
| 2018-12-31 | NZ$0.44 B | 6.13% |
| 2017-12-31 | NZ$0.41 B | |
| 2016-06-30 | NZ$0.39 B | -13.84% |
| 2015-06-30 | NZ$0.45 B | 140.74% |
| 2014-06-30 | NZ$0.18 B | -31.66% |
| 2013-06-30 | NZ$0.27 B | 22.86% |
| 2012-06-30 | NZ$0.22 B | -14.48% |
| 2011-06-30 | NZ$0.26 B | 32.45% |
| 2010-06-30 | NZ$0.19 B | 26.28% |
| 2009-06-30 | NZ$0.15 B | 43.39% |
| 2008-06-30 | NZ$0.10 B | 4.72% |
| 2007-06-30 | NZ$0.10 B | -32.69% |
| 2006-06-30 | NZ$0.15 B | -3.48% |
| 2005-06-30 | NZ$0.16 B | -16.02% |
| 2004-06-30 | NZ$0.19 B | -5.43% |
| 2003-06-30 | NZ$0.20 B | -35.24% |
| 2002-06-30 | NZ$0.31 B | -20.03% |
| 2001-06-30 | NZ$0.39 B |
Total Assets for similar companies or competitors
| Company | Total assets | differencediff. | Country |
|---|---|---|---|
 Seagen
SGEN | NZ$5.99 B | 342.07% | 🇺🇸 USA |
 Amgen AMGN | NZ$147.33 B | 10,770.56% | 🇺🇸 USA |
 Eli Lilly LLY | NZ$147.37 B | 10,773.21% | 🇺🇸 USA |
 Bristol-Myers Squibb BMY | NZ$152.38 B | 11,142.78% | 🇺🇸 USA |
 Johnson & Johnson JNJ | NZ$319.30 B | 23,458.05% | 🇺🇸 USA |
 Pfizer PFE | NZ$342.97 B | 25,204.43% | 🇺🇸 USA |
 Novartis NVS | NZ$164.77 B | 12,056.78% | 🇨🇭 Switzerland |
 Sanofi SNY | NZ$235.25 B | 17,256.99% | 🇫🇷 France |